Sriharsha Kantamneni
Hado Therapeutics
Dr Sriharsha Kantamneni is a neuroscientist and biotech entrepreneur leading Hado Therapeutics at the University of Bradford’s Institute of Cancer Therapeutics (ICT). He focuses on translating discovery science into first-in-class small-molecule medicines for diseases with extreme unmet needs. At Hado, he is advancing HT8457, a dual-target, candidate for glioblastoma that combines immune activation (A2AR blockade) with tumour-survival pathway inhibition (mGlu5R). Harsha collaborates with partners, including Eurofins and PPD Thermo Fisher, to deliver a capital-efficient IND pathway, leveraging institutional support, rigorous preclinical validation, and a clear out-licensing strategy.
About the Enterprise
Glioblastoma (GBM) is the most aggressive primary brain cancer, with fewer than 5% of patients surviving beyond five years. Current therapies largely target single pathways, resulting in limited durability and rapid tumour resistance.
HT8457 is a first-in-class, dual-target small molecule that simultaneously reactivates anti-tumour immunity through A2A receptor blockade while suppressing tumour survival via mGlu5 receptor antagonism. This coordinated “Double Tap” approach is designed for oral delivery, brain penetration, and scalable chemistry, aligning with modern pharma development and out-licensing models.
Over the next 5–10 years, Hado Therapeutics aims to deliver an IND-ready GBM asset and expand the dual-target platform across neuro-oncology and neurology indications, creating multiple value-inflexion points through strategic partnerships and licensing.
Achievements
& Highlights
-
£95,000 committed director investment.
​
-
£15,000 Innovate UK EDGE Grant secured (early commercial validation).
​
-
£18,000 Innovate UK Biomedical Catalyst – Future Medicines Accelerator Grant secured.
​
-
Partnerships in place with Eurofins and PPD Thermo Fisher for IND-enabling studies.
Contact
Got an idea, question, or collaboration in mind? Let’s connect.
